Tag: Hans Keirstead
The world’s first test on patients of a treatment for spinal cord injury using human embryonic stem cells is so far proving safe, one year after the first of four patients received injections.
The treatment, developed by researchers at UC Irvine, involves injection of neural cells derived from human embryonic stem cells into the site of a spinal cord injury within seven to 14 days — known as “acute” injuries, as opposed to longer-term injuries known as “chronic.”
None of the patients has experienced any adverse reactions from the treatment, according to Geron Corp., which is conducting the trials, although a few “mild” adverse reactions were reported from a drug used to suppress the patients’ immune responses.
UCI’s Hans Keirstead discusses how embryonic stem cell therapy restores walking ability in rats with neck injuries. Video by Kerrin Piche Serna, University Communications.